Other

National Hospital Organization Kinki-Chuo Chest Medical Center

Azbio Corporation

Chugai Seiyaku Kabushiki Kaisha

Shinshu University

Microbial Chemistry Research Foundation

Infectious Disease Research Institute

National Hospital Organization

Okada, Masaji

Takamori, Yasushi

Masaji Okada

Kazuyuki Ogawa

Kinya Nagata

Yasushi Takamori

Yoshiaki Takahashi

Masayuki Igarashi

Masahiko Mihara

Yoshiyuki Ohsugi

Masafumi Takahashi

Atsushi Izawa

(Problems) To provide a therapeutic agent for infections comprising granulysin as an active ingredient which has little side effect and no cytotoxicity and to which bacteria can hardly acquire resistance, and a treatment method using the same. (Means for Solving Problems) The present invention provides a therapeutic agent for infections comprising as active ingredient: 15K granulysin, a combination of 15K granulysin and 15K granulysin in vivo expression vector, a combination of 15K granulysin and at least one interleukin selected from IL-6, IL-23 or IL-27, a combination of 15K granulysin in vivo expression vector and at least one interleukin selected from IL-6, IL-23 or IL-27, or a combination of 15K granulysin in vivo expression vector and HSP65DNA and IL-12DNA in vivo expression vector, which enhances killing effects on bacteria and has less side effect, and to which bacteria can hardly acquire resistance, and a treatment method using the same.

Therapeutic agent for infections, and treatment method using same

A method for treating an individual infected with XDR-TB, the method including administering to the individual an anti-XDR-TB drug which comprises a compound having a structure expressed by Structural Formula (1) below: 

Anti-XDR-TB drug, anti-MDR-TB drug, and combination anti-tuberculosis drug

The effect of anti-IL-6 receptor antibodies in suppressing cytotoxic T cell induction was examined. The results showed that CTL activity against alloantigens was statistically significantly reduced in mice treated with anti-IL-6 receptor antibodies as compared to mice not treated with antibodies and mice treated with a control antibody. The anti-IL-6 receptor antibody was also administered to recipients of a mouse model for allogenic heart transplantation. As a result, histopathological findings showed that inflammatory cell infiltration into transplanted hearts was suppressed and the survival period of transplanted hearts was significantly prolonged. Thus, the present inventors for the first time discovered that administration of anti-IL-6 receptor antibodies could suppress cytotoxic T cell induction and thereby suppress acute rejection after transplantation.

Methods for suppressing acute rejection of a heart transplant

Therapeutic agent for infections, and treatment method using the same

Growing community of inventors

Osaka, Japan

Masaji Okada